A Study of LY4515100 in Healthy Male Participants
A Phase 1, Open-Label, 2-Part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [¹⁴C]-LY4515100 in Healthy Male Participants
The main purpose of this study is to evaluate how the body handles [¹⁴C]-LY4515100. The study will investigate how much [¹⁴C]-LY4515100 enters the bloodstream from the stomach or intestines and is available to have an effect on the body, how the body changes [¹⁴C]-LY4515100 so that it can be used or removed, and how the body gets rid of [¹⁴C]-LY4515100. For each participant, the study will last about 9 weeks and will include a Clinical Research Unit (CRU) stay lasting between 10 and 30 days.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- 电话号码:1-317-615-4559
- 邮箱:LillyTrials@Lilly.com
研究联系人备份
- 姓名:Physicians interested in becoming principal investigators please contact
- 邮箱:clinical_inquiry_hub@lilly.com
学习地点
-
-
Wisconsin
-
Madison、Wisconsin、美国、53704
- 招聘中
- Fortrea Clinical Research Unit
-
首席研究员:
- Kimberly Cruz
-
接触:
- 电话号码:608-442-8200
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Are overtly healthy as determined by medical evaluation.
- Have a body mass index (BMI) within the range of 18.0 to 35.0 kilograms per square meter (kg/m²), inclusive.
Exclusion Criteria:
- Have significant previous or current history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinal, hematological, neurological, thromboembolism, or bleeding disorder capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study intervention; or of interfering with the interpretation of data.
- Have a significant history of or current psychiatric disorders.
- Have history of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs. Uncomplicated appendectomy and hernia repair will be allowed.
- Have a history of constipation or have had acute constipation within 3 weeks prior to check-in.
- Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing, for example, serial x-ray or computed tomography scans, barium meal, or current employment in a job requiring radiation exposure monitoring.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:[¹⁴C]-LY4515100 Part 1
[¹⁴C]-LY4515100 containing radioactivity administered orally |
[¹⁴C]-LY4515100 administered orally |
|
实验性的:LY4515100 + [¹⁴C]-LY4515100 Part 2
LY4515100 administered orally with [¹⁴C]-LY4515100 containing radioactivity administered intravenously (IV) |
LY4515100 administered orally [¹⁴C]-LY4515100 administered IV |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Part 1: Urinary Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
大体时间:Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 1: Fecal Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
大体时间:Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 2: Dose Normalized Ratio of the Area Under the Concentration-Time Curve After Oral Administration (AUCpo) to Area Under the Concentration-Time Curve After Intravenous Administration (AUCiv) of LY4515100
大体时间:Predose Up to Day 14
|
Predose Up to Day 14
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Part 1: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Total Plasma Radioactivity
大体时间:Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 1: PK: Maximum Concentration (Cmax) of Total Plasma Radioactivity
大体时间:Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 1: Total Radioactivity Recovered in Urine, Feces, and Expired Air
大体时间:Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 1: Total Number of Metabolites of LY4515100 in Urine, Feces, and Plasma
大体时间:Predose Up to Day 14
|
Predose Up to Day 14
|
|
Part 2: PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of [¹⁴C]-LY4515100
大体时间:Predose Up to Day 9
|
Predose Up to Day 9
|
|
Part 2: PK: Maximum Concentration (Cmax) of [¹⁴C]-LY4515100
大体时间:Predose Up to Day 9
|
Predose Up to Day 9
|
|
Part 2: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Total Plasma Radioactivity
大体时间:Predose Up to Day 9
|
Predose Up to Day 9
|
|
Part 2: PK: Maximum Concentration (Cmax) of Total Plasma Radioactivity
大体时间:Predose Up to Day 9
|
Predose Up to Day 9
|
合作者和调查者
调查人员
- 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 27791
- J6V-MC-OIAC (其他标识符:Eli Lilly and Company)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.